Rachel E. Sanborn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachel E. Sanborn has a total of 551 co-authors. Here are the top co-authors by number of shared publications:
- Alexander I. Spira
Virginia Cancer Specialists Research Institute, Fairfax, VA
33 shared publications - Manish R. Sharma
START Center for Cancer Research - Midwest, Grand Rapids, MI, USA
32 shared publications - Anthony W. Tolcher
NEXT Oncology, San Antonio, Texas
31 shared publications - Brianne O’NEill
Inhibrx Biosciences, Inc. 15 , La Jolla, California
31 shared publications - D. Ross Camidge
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
31 shared publications - David Berz
Valkyrie Clinical Trials, Los Angeles, California
31 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Phase I Dose Escalation and Cohort Expansion of Lorigerlimab, a Bispecific PD-1 × CTLA-4 DART Molecule With Focus on Metastatic Castration-Resistant Prostate Cancer
PURPOSE: Dual blockade of PD-(L)1 and cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) increases antitumor activity beyond checkpoint inhibitor monotherapies, but substantially increases toxicity, limiting potential for long-term outcomes and combination strategies. Lorigerlimab is an investigational bispecific PD-1 × CTLA-4 DART molecule designed to enhance CTLA-4 binding to T cells in the tumor microenvironment and limit T-cell binding in normal tissue to increase tolerability. METHODS: A phase I, dose-escalation/cohort-expansion study (ClinicalTrials.gov identifier: NCT03761017 ) evaluated lorigerlimab in advanced solid tumors. Safety was the primary end point; secondary end points included antitumor activity, pharmacokinetics, immunogenicity, and pharmacodynamics. Doses evaluated during dose escalation: 0.1-10.0 mg/kg. The recommended dose for expansion (RDE) was investigated in four cohorts. Objective response was assessed per RECIST v1.1 in all cohorts, and prostate-specific antigen (PSA) response was evaluated in the metastatic castration-resistant prostate cancer (mCRPC) cohort. RESULTS: Overall, 162 patients received ≥1 lorigerlimab dose, including 127 who received lorigerlimab at the RDE of 6 mg/kg IV once every 3 weeks. All-grade treatment-related adverse event (TRAEs) occurred in 85.8% of the 162 patients (139/162), with grade ≥3 TRAEs in 36.4%. Rates of immune-related adverse events (AEs) were 34.6% (all grades) and 13.4% (grade ≥3), and 24.7% of the patients experienced AEs resulting in lorigerlimab discontinuation. Objective responses were observed in all expansion cohorts: mCRPC (25.0%, 9/36); melanoma (11.9%, 5/42); checkpoint naïve non–small cell lung cancer (21.4%, 3/14); and microsatellite stable colorectal cancer (5.0%, 1/20). The PSA50 response rate in mCRPC was 28.6% (12/42). Objective responses in mCRPC were associated with increased expression of inducible costimulator in CD4 + and Ki67 in circulating T cells. CONCLUSION: Lorigerlimab demonstrated a manageable safety profile for the dual PD-(L)1/CTLA-4 targeting strategy, and antitumor activity was observed in all expansion indications. Durable objective and PSA50 response rates were observed in mCRPC. A lorigerlimab phase II in mCRPC is ongoing.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Open AccessPhase I Dose Escalation and Cohort Expansion of Lorigerlimab, a Bispecific PD-1 × CTLA-4 DART Molecule With Focus on Metastatic Castration-Resistant Prostate Cancer
PURPOSE: Dual blockade of PD-(L)1 and cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) increases antitumor activity beyond checkpoint inhibitor monotherapies, but substantially increases toxicity, limiting potential for long-term outcomes and combination strategies. Lorigerlimab is an investigational bispecific PD-1 × CTLA-4 DART molecule designed to enhance CTLA-4 binding to T cells in the tumor microenvironment and limit T-cell binding in normal tissue to increase tolerability. METHODS: A phase I, dose-escalation/cohort-expansion study (ClinicalTrials.gov identifier: NCT03761017 ) evaluated lorigerlimab in advanced solid tumors. Safety was the primary end point; secondary end points included antitumor activity, pharmacokinetics, immunogenicity, and pharmacodynamics. Doses evaluated during dose escalation: 0.1-10.0 mg/kg. The recommended dose for expansion (RDE) was investigated in four cohorts. Objective response was assessed per RECIST v1.1 in all cohorts, and prostate-specific antigen (PSA) response was evaluated in the metastatic castration-resistant prostate cancer (mCRPC) cohort. RESULTS: Overall, 162 patients received ≥1 lorigerlimab dose, including 127 who received lorigerlimab at the RDE of 6 mg/kg IV once every 3 weeks. All-grade treatment-related adverse event (TRAEs) occurred in 85.8% of the 162 patients (139/162), with grade ≥3 TRAEs in 36.4%. Rates of immune-related adverse events (AEs) were 34.6% (all grades) and 13.4% (grade ≥3), and 24.7% of the patients experienced AEs resulting in lorigerlimab discontinuation. Objective responses were observed in all expansion cohorts: mCRPC (25.0%, 9/36); melanoma (11.9%, 5/42); checkpoint naïve non–small cell lung cancer (21.4%, 3/14); and microsatellite stable colorectal cancer (5.0%, 1/20). The PSA50 response rate in mCRPC was 28.6% (12/42). Objective responses in mCRPC were associated with increased expression of inducible costimulator in CD4 + and Ki67 in circulating T cells. CONCLUSION: Lorigerlimab demonstrated a manageable safety profile for the dual PD-(L)1/CTLA-4 targeting strategy, and antitumor activity was observed in all expansion indications. Durable objective and PSA50 response rates were observed in mCRPC. A lorigerlimab phase II in mCRPC is ongoing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S3 summarizes the treatment-emergent adverse events
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S3 summarizes the treatment-emergent adverse events
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S2 shows patient disposition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S2 shows patient disposition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S5 is a schematic of the study design
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S5 is a schematic of the study design
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S4 shows that addition of an orthogonal anti–PD-1 antibody to INBRX-105-a resulted in enhanced antitumor activity in mouse tumor models and improved blockade of PD-1/PD-L1 interactions compared with INBRX-105-a alone
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S4 shows that addition of an orthogonal anti–PD-1 antibody to INBRX-105-a resulted in enhanced antitumor activity in mouse tumor models and improved blockade of PD-1/PD-L1 interactions compared with INBRX-105-a alone
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S2 shows that in vitro INBRX-105 resulted in greater T-cell modulation than a constitutive 4-1BB agonist that was provided alone or in combination with a PD-L1 antagonist
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S2 shows that in vitro INBRX-105 resulted in greater T-cell modulation than a constitutive 4-1BB agonist that was provided alone or in combination with a PD-L1 antagonist
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S1 summarizes the representativeness of study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S1 summarizes the representativeness of study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S7 summarizes the characteristics of patients who were responders to study treatment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S7 summarizes the characteristics of patients who were responders to study treatment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S3 shows that INBRX-105-a, a murine INBRX-105 surrogate, demonstrated potent antitumor activity, including T-cell tumor infiltration and induction of T-cell memory, in PD-L1+ mouse tumor models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Figure S3 shows that INBRX-105-a, a murine INBRX-105 surrogate, demonstrated potent antitumor activity, including T-cell tumor infiltration and induction of T-cell memory, in PD-L1+ mouse tumor models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S4 summarizes the INBRX-105–related hepatic treatment-emergent adverse events
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Table S4 summarizes the INBRX-105–related hepatic treatment-emergent adverse events